Prof. Yi Ba 巴一
Chief Physician, Professor
Department of Medical Oncology, Peking Union Medical College Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of digestive tract tumors, including chemotherapy, targeted therapy, and immunotherapy.
Dr. Ba is Director of Medical Oncology at Peking Union Medical College Hospital. After postdoctoral research at Scripps Research Institute (2002), Dr. Ba focused on digestive system tumors. Dr. Ba has led or participated in nearly 100 multicenter clinical trials and received provincial first-class awards for scientific progress. Dr. Ba contributes to multiple medical guidelines and textbooks.
Professional roles
- Former Chair, Supportive Care Committee, China Anti-Cancer Association
- Vice Chair, Clinical Chemotherapy Committee, China Anti-Cancer Association
- Vice Chair, Clinical Drug Research Committee, China Anti-Cancer Association
- Vice President, Oncology Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Ba Yi). Papers usually list the name as Yi Ba or Ba Y.
Selected publications
50 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Ann Surg Oncol, 2026 (senior author): Assessing Graded Histological Regression as Basis for Treatment Modification after Neoadjuvant Therapy in LAGC: An Exploratory Phase II Study. PubMed 42563121
- Cancer Med, 2026 (senior author): Distinct Germline Mutation Landscape and Clinical Implications in Chinese Colorectal Cancer: A Large-Scale Genomic Analysis of 1094 Patients. PubMed 42204638
- Aging Dis, 2026 (senior author): Cellular Senescence in Gastric Cancer: Molecular Mechanisms, Microenvironment Remodeling and Therapeutic Implications. PubMed 41910653
- Chin Clin Oncol, 2026 (senior author): Treatment of metastatic pancreatic cancer with concurrent BRAF V600E mutation and germline BRCA2 mutation: a case report. PubMed 41797461
- Cancer Lett, 2025 (senior author): An anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) and chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer: A phase Ib study. PubMed 41005455
- World J Clin Oncol, 2025 (senior author): Perioperative immunotherapy combined with standard therapy for human epidermal growth factor receptor 2-positive locally advanced gastric cancer: A case report. PubMed 41355925
- Cancer Med, 2025 (senior author): Serum Pepsinogen as a Biomarker of Gastrointestinal Stromal Tumors (GIST) in Stomach. PubMed 40899470
- Cancer, 2025 (senior author): Anti-PD-1 antibody (SCT-I10A) plus anti-EGFR antibody (SCT200) in patients with advanced esophageal squamous cell carcinoma: A multicenter, open-label, phase 1b clinical trial. PubMed 40819238
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion